Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants - Trial NCT06417229
Access comprehensive clinical trial information for NCT06417229 through Pure Global AI's free database. This Phase 1 trial is sponsored by Celgene and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 82 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Celgene
Timeline & Enrollment
Phase 1
May 16, 2024
Dec 10, 2024
Primary Outcome
Maximum observed plasma concentration (Cmax),Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)],Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects
 and relative bioavailability of BMS-986365 in healthy male participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06417229
Non-Device Trial